163 related articles for article (PubMed ID: 7591900)
1. RTOG's first quality of life study--RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer.
Watkins-Bruner D; Scott C; Lawton C; DelRowe J; Rotman M; Buswell L; Beard C; Cella D
Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):901-6. PubMed ID: 7591900
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial.
Chen RC; Zhang Y; Chen MH; McMahon E; Loffredo M; McPherson CP; Nguyen AU; Nguyen PL; D'Amico AV
BJU Int; 2012 Dec; 110(11):1690-5. PubMed ID: 22502770
[TBL] [Abstract][Full Text] [Related]
3. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
[TBL] [Abstract][Full Text] [Related]
4. Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20).
Lawton CA; Coleman CN; Buzydlowski JW; Forman JD; Marcial VA; DelRowe JD; Rotman M
Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):673-80. PubMed ID: 8948352
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05.
Feigenberg SJ; Lee WR; Desilvio ML; Winter K; Pisansky TM; Bruner DW; Lawton C; Morton G; Baikadi M; Sandler H
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):956-64. PubMed ID: 15989995
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
[TBL] [Abstract][Full Text] [Related]
8. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
[TBL] [Abstract][Full Text] [Related]
9. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
[TBL] [Abstract][Full Text] [Related]
10. Patient self-assessment of complications and quality of life after conformal neutron and photon irradiation for localized prostate cancer.
Reddy SM; Ruby J; Wallace M; Forman JD
Radiat Oncol Investig; 1997; 5(5):252-6. PubMed ID: 9372548
[TBL] [Abstract][Full Text] [Related]
11. Rectal function following brachytherapy with or without supplemental external beam radiation: results of two prospective randomized trials.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Kurko B; Cleavinger S
Brachytherapy; 2003; 2(3):147-57. PubMed ID: 15062137
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
[TBL] [Abstract][Full Text] [Related]
13. Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy.
Muanza TM; Albert PS; Smith S; Godette D; Crouse NS; Cooley-Zgela T; Sciuto L; Camphausen K; Coleman CN; Ménard C
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1316-21. PubMed ID: 16029787
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of results of p(65)+Be neutron therapy for treatment of prostate adenocarcinoma at the cyclotron of Louvain-la-Leuve. Part II: Side effects and their influence on quality of life measured with QLQ-C30 of EORTC.
Scalliet PG; Remouchamps V; Curran D; Ledent G; Wambersie A; Richard F; van Cangh P
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1549-61. PubMed ID: 15050336
[TBL] [Abstract][Full Text] [Related]
15. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas.
Lee DJ; Cosmatos D; Marcial VA; Fu KK; Rotman M; Cooper JS; Ortiz HG; Beitler JJ; Abrams RA; Curran WJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):567-76. PubMed ID: 7790241
[TBL] [Abstract][Full Text] [Related]
16. [Quality of life after radiotherapy for prostate cancer].
Joly F; Degrendel AC; Guizard AV
Cancer Radiother; 2010 Oct; 14(6-7):519-25. PubMed ID: 20728393
[TBL] [Abstract][Full Text] [Related]
17. Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer.
Lee WR; McQuellon RP; Case LD; deGuzman AF; McCullough DL
J Urol; 1999 Aug; 162(2):403-6. PubMed ID: 10411047
[TBL] [Abstract][Full Text] [Related]
18. High-dose intensity-modulated radiotherapy as primary therapy for prostate cancer: report on dosimetry aspects and acute toxicity in the Indian scenario.
De S; Kannan V; Deshpande S; Anand V; Ghadi Y
J Cancer Res Ther; 2010; 6(1):58-64. PubMed ID: 20479549
[TBL] [Abstract][Full Text] [Related]
19. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
20. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
